Cargando…

Pyrosequencing Dried Blood Spots Reveals Differences in HIV Drug Resistance between Treatment Naïve and Experienced Patients

Dried blood spots (DBS) are an alternative specimen collection format for HIV-1 genotyping. DBS produce HIV genotyping results that are robust and equivalent to plasma when using conventional sequencing methods. However, using tagged, pooled pyrosequencing, we demonstrate that concordance between pl...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Hezhao, Li, Yang, Liang, Binhua, Pilon, Richard, MacPherson, Paul, Bergeron, Michèle, Kim, John, Graham, Morag, Van Domselaar, Gary, Sandstrom, Paul, Brooks, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3567018/
https://www.ncbi.nlm.nih.gov/pubmed/23409150
http://dx.doi.org/10.1371/journal.pone.0056170
_version_ 1782258643210600448
author Ji, Hezhao
Li, Yang
Liang, Binhua
Pilon, Richard
MacPherson, Paul
Bergeron, Michèle
Kim, John
Graham, Morag
Van Domselaar, Gary
Sandstrom, Paul
Brooks, James
author_facet Ji, Hezhao
Li, Yang
Liang, Binhua
Pilon, Richard
MacPherson, Paul
Bergeron, Michèle
Kim, John
Graham, Morag
Van Domselaar, Gary
Sandstrom, Paul
Brooks, James
author_sort Ji, Hezhao
collection PubMed
description Dried blood spots (DBS) are an alternative specimen collection format for HIV-1 genotyping. DBS produce HIV genotyping results that are robust and equivalent to plasma when using conventional sequencing methods. However, using tagged, pooled pyrosequencing, we demonstrate that concordance between plasma and DBS is not absolute and varies according to viral load (VL), duration of HIV infection and antiretroviral therapy (ART) status. The plasma/DBS concordance is the highest when VL is ≥5,000 copies/ml and/or the patient has no ART exposure and/or when the duration of HIV infection is ≤2 years. Stepwise regression analysis revealed that VL is most important independent predictor for concordance of DBS with plasma genotypes. This is the first study to use next generation sequencing to identify discordance between DBS and plasma genotypes. Consideration should be given to VL, duration of infection, and ART exposure when interpreting DBS genotypes produced using next generation sequencing. These findings are of particular significance when DBS are to be used for clinical monitoring purposes.
format Online
Article
Text
id pubmed-3567018
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-35670182013-02-13 Pyrosequencing Dried Blood Spots Reveals Differences in HIV Drug Resistance between Treatment Naïve and Experienced Patients Ji, Hezhao Li, Yang Liang, Binhua Pilon, Richard MacPherson, Paul Bergeron, Michèle Kim, John Graham, Morag Van Domselaar, Gary Sandstrom, Paul Brooks, James PLoS One Research Article Dried blood spots (DBS) are an alternative specimen collection format for HIV-1 genotyping. DBS produce HIV genotyping results that are robust and equivalent to plasma when using conventional sequencing methods. However, using tagged, pooled pyrosequencing, we demonstrate that concordance between plasma and DBS is not absolute and varies according to viral load (VL), duration of HIV infection and antiretroviral therapy (ART) status. The plasma/DBS concordance is the highest when VL is ≥5,000 copies/ml and/or the patient has no ART exposure and/or when the duration of HIV infection is ≤2 years. Stepwise regression analysis revealed that VL is most important independent predictor for concordance of DBS with plasma genotypes. This is the first study to use next generation sequencing to identify discordance between DBS and plasma genotypes. Consideration should be given to VL, duration of infection, and ART exposure when interpreting DBS genotypes produced using next generation sequencing. These findings are of particular significance when DBS are to be used for clinical monitoring purposes. Public Library of Science 2013-02-07 /pmc/articles/PMC3567018/ /pubmed/23409150 http://dx.doi.org/10.1371/journal.pone.0056170 Text en © 2013 Ji et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Ji, Hezhao
Li, Yang
Liang, Binhua
Pilon, Richard
MacPherson, Paul
Bergeron, Michèle
Kim, John
Graham, Morag
Van Domselaar, Gary
Sandstrom, Paul
Brooks, James
Pyrosequencing Dried Blood Spots Reveals Differences in HIV Drug Resistance between Treatment Naïve and Experienced Patients
title Pyrosequencing Dried Blood Spots Reveals Differences in HIV Drug Resistance between Treatment Naïve and Experienced Patients
title_full Pyrosequencing Dried Blood Spots Reveals Differences in HIV Drug Resistance between Treatment Naïve and Experienced Patients
title_fullStr Pyrosequencing Dried Blood Spots Reveals Differences in HIV Drug Resistance between Treatment Naïve and Experienced Patients
title_full_unstemmed Pyrosequencing Dried Blood Spots Reveals Differences in HIV Drug Resistance between Treatment Naïve and Experienced Patients
title_short Pyrosequencing Dried Blood Spots Reveals Differences in HIV Drug Resistance between Treatment Naïve and Experienced Patients
title_sort pyrosequencing dried blood spots reveals differences in hiv drug resistance between treatment naïve and experienced patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3567018/
https://www.ncbi.nlm.nih.gov/pubmed/23409150
http://dx.doi.org/10.1371/journal.pone.0056170
work_keys_str_mv AT jihezhao pyrosequencingdriedbloodspotsrevealsdifferencesinhivdrugresistancebetweentreatmentnaiveandexperiencedpatients
AT liyang pyrosequencingdriedbloodspotsrevealsdifferencesinhivdrugresistancebetweentreatmentnaiveandexperiencedpatients
AT liangbinhua pyrosequencingdriedbloodspotsrevealsdifferencesinhivdrugresistancebetweentreatmentnaiveandexperiencedpatients
AT pilonrichard pyrosequencingdriedbloodspotsrevealsdifferencesinhivdrugresistancebetweentreatmentnaiveandexperiencedpatients
AT macphersonpaul pyrosequencingdriedbloodspotsrevealsdifferencesinhivdrugresistancebetweentreatmentnaiveandexperiencedpatients
AT bergeronmichele pyrosequencingdriedbloodspotsrevealsdifferencesinhivdrugresistancebetweentreatmentnaiveandexperiencedpatients
AT kimjohn pyrosequencingdriedbloodspotsrevealsdifferencesinhivdrugresistancebetweentreatmentnaiveandexperiencedpatients
AT grahammorag pyrosequencingdriedbloodspotsrevealsdifferencesinhivdrugresistancebetweentreatmentnaiveandexperiencedpatients
AT vandomselaargary pyrosequencingdriedbloodspotsrevealsdifferencesinhivdrugresistancebetweentreatmentnaiveandexperiencedpatients
AT sandstrompaul pyrosequencingdriedbloodspotsrevealsdifferencesinhivdrugresistancebetweentreatmentnaiveandexperiencedpatients
AT brooksjames pyrosequencingdriedbloodspotsrevealsdifferencesinhivdrugresistancebetweentreatmentnaiveandexperiencedpatients